Hypolipidemia induced by PPARα agonists: HNF-4α as an alternative to PPARα

Current Opinion in Investigational Drugs

Volumn 5, Issue 9, 2004, Pages 941-946

  Bar Tana, Jacob ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

HNF 4 hypolipidemia, PPAR

Indexed keywords

ANTILIPEMIC AGENT; DNA BINDING PROTEIN; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOPROTEIN; TRANSCRIPTION FACTOR;

ANIMAL; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSCRIPTION; HUMAN; LIVER; METABOLISM; REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; DNA-BINDING PROTEINS; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; LIVER; PHOSPHOPROTEINS; PPAR ALPHA; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 16644363226     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Fruchart K, Brewer HB Jr, Leitersdorf E: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol (1998) 81(7):912-917.
2. Vosper H, Khoudoli GA, Graham TL, Palmer CN: Peroxisome proliferator-activated receptor agonists, hyperlipidaemia and atherosclerosis. Pharmacol Ther (2002) 95(1):47-62.
3. Elisaf M: Effects of fibrates on serum metabolic parameters. Curr Med Res Opin (2002) 18(5):269-276.
4. Bremer J: The biochemistry of hypo- and hyperlipidemic fatty acid derivatives: Metabolism and metabolic effects. Prog Lipid Res (2001) 40(4):231-268.
5. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res (1996) 37(5):907-925.
6. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 98(19):2088-2093.
7. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev (1999) 20(5):649- 688.
8. Vamecq J, Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet (1999) 354(9173):141- 148.
9. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature (2000) 405(6785):421-424.
10. Corton JC, Anderson SP, Stauber A: Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol (2000) 40:491-518.
11. Gervois P, Torra IP, Fruchart JC, Staels B: Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med (2000) 38(1):3-11.
12. Kliewer SA, Xu HE, Lambert MH, Willson TM: Peroxisome proliferator-activated receptors: From genes to physiology. Recent Prog Horm Res (2001) 56:239-263.
13. Reddy JK, Hashimoto T: Peroxisomal P-oxidation and peroxisome proliferator-activated receptor a: An adaptive metabolic system. Annu Rev Nutr (2001) 21:193-230.
14. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med (2002) 53:409-435.
15. Lawrence JW, Eacho P: In: Toxicology of the Liver. Plaa GL, Hewitt WR (Eds), Taylor and Francis, Washington, DC, USA (1998):125-157.
16. Roberts-Thomson SJ: Peroxisome proliferator-activated receptors in tumorigenesis: Targets of tumour promotion and treatment. Immunol Cell Biol (2000) 78(4):436-441.
17. Hertz R, Berman I, Bar-Tana J: Transcriptional activation by amphipathic carboxylic peroxisomal proliferators is induced by the free acid rather than the acyl-CoA derivative. Eur J Biochem (1994) 221(1):611-615.
18. Ide T, Ontko JA: Increased secretion of very low density lipoprotein triglyceride following inhibition of long chain fatty acid oxidation in isolated rat liver. J Biol Chem (1981) 256(20):10247-10255.
19. Yamamoto M, Fukuda N, Triscari J, Sullivan AC, Ontko JA: Decreased hepatic production of very low density lipoproteins following activation of fatty acid oxidation by Ro 22-0654. J Lipid Res (1985) 26(10):1196-1204.
20. Ginsberg HN: Lipoprotein physiology. Endocrinol Metab Clin North Am (1998) 27(3):503-519.
21. Hertz R, Bishara-Shieban J, Bar-Tana J: Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem (1995) 270(22):13470-13475.
22. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J: Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest (1995) 95(2):705-712.
23. Raspe E, Duez H, Mansen A, Fontaine C, Fievet C, Fruchart JC, Vennstrom B, Staels B: Identification of Rev-erba as a physiological repressor of apoC-III gene transcription. J Lipid Res (2002) 43(12):2172- 2179.
24. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor a-deficient mice. J Biol Chem (1997) 272(43):27307-27312.
25. Reddy JK, Lalwani ND: Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit Rev Toxicol (1983) 12(1):1-58.
26. Hertz R, Bar-Tana J: Peroxisome proliferator-activated receptor (PPAR)α activation and its consequences in humans. Toxicol Lett (1998) 102-103:85-90.
27. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W: Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol (1998) 27(1Pt1):47-60.
28. Holden PR, Tugwood JD: Peroxisome proliferator-activated receptor a: Role in rodent liver cancer and species differences. J Mol Endocrinol (1999) 22(1):1-8.
29. Hertz R, Arnon J, Hoter A, Shouval D, Bar-Tana J: Clofibrate does not induce peroxisomal proliferation in human hepatoma cell lines PLC/PRF/5 and SK-HEP-1. Cancer Lett (1987) 34(3):263-272.
30. Roglans N, Bellido A, Rodriguez C, Cabrero A, Novell F, Ros E, Zambon D, Laguna JCL: Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin Pharmacol Ther (2002) 72(6):692-701.
31. Woodyatt NJ, Lambe KG, Myers KA, Tugwood JD, Roberts RA: The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: Significance for species differences in response to PPs. Carcinogenesis (1999) 20(3):369-372.
32. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF: Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol (1998) 53(1):14-22.
33. Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ: Peroxisome proliferator-activated receptors: Structures and function. Ann NY Acad Sci (1996) 804:252-265.
34. Gervois P, Torra IP, Chinetti G, Grotzinger T, Dubois G, Fruchart JC, Fruchart-Najib J, Leitersdorf E, Staels B: A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity. Mol Endocrinol (1999) 13(9):1535-1549.
35. Hsu M-H, Savas U, Griffin KJ, Johnson EF: Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor α in HepG2 cells. J Biol Chem (2001) 276(30):27950-27958.
36. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, Zhou G: Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR)α. PPARα fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J Biol Chem (2001) 276(34):31521-31527.
37. Sladek FM: Hepatocyte nuclear factor 4 (HNF-4). In: Liver Gene Expression. Tronche F, Yaniv M (Eds), VRG Landes Co, Austin, TX, USA (1994):207-230.
38. Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, Prezioso VR, Bchvarova RE, Darnell JE Jr: Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev (1994) 8(20):2466- 2477.
39. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, Fajans SS, Signorini S, Stoffel M, Bell GI: Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1). Nature (1996) 384(6608):458-460.
40. Hertz R, Magenheim J, Berman I, Bar-Tana J: Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4α. Nature (1998) 392(6675):512-516.
41. Petrescu AD, Hertz R, Bar-Tana J, Schroeder F, Kier AB: Ligand specificity and conformational dependence of the hepatic nuclear factor-4α (HNF-4α). J Biol Chem (2002) 277(27):23988-23999.
42. Dhe-Paganon S, Duda K, Iwamoto M, Chi YI, Shoelson SE: Crystal structure of the HNF-4α ligand binding domain in complex with endogenous fatty acid ligand. J Biol Chem (2002) 277(41):37973-37976.
43. Hertz R, Sheena V, Kalderon B, Berman I, Bar-Tana J: Suppression of hepatocyte nuclear factor-4α by acyl-CoA thioesters of hypolipidemic peroxisome proliferators. Biochem Pharmacol (2001) 61(9):1057-1062.
44. Hertz R, Ben-Haim N, Petrescu AD, Kalderon B, Berman I, Eldad N, Schroeder F, Bar-Tana J: Rescue of MODY-1 by agonist ligands of hepatocyte nuclear factor-4α. J Biol Chem (2003) 278(25):22578- 22585.
45. Kalderon B, Sheena V, Shachrur S, Hertz R, Bar-Tana J: Modulation by nutrients and drugs of liver acyl-CoAs analyzed by mass spectrometry. J Lipid Res (2002) 43(7):1125-1132.
46. Elholm M, Garras A, Neve S, Tornehave D, Lund TB, Skorve J, Flatmark T, Kristiansen K, Berge RK: Long-chain acyl-CoA esters and acyl-CoA binding protein are present in the nucleus of rat liver cells. J Lipid Res (2000) 41(4):538-545.
47. Petrescu AD, Payne HR, Boedecker A, Chao H, Hertz R, Bar-Tana J, Schroeder F, Kier AB: Physical and functional interaction of acyl-CoA-binding protein with hepatocyte nuclear factor-4α. J Biol Chem (2003) 278(31):51813-51824.
48. Knights KM, Drogemuller CJ: Xenobiotic-CoA ligases: Kinetic and molecular characterization. Curr Drug Metab (2000) 1(1):49-66.
49. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ: Hepatocyte nuclear factor 4-α (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol (2001) 21 (4):1393-1403.
50. Elholm M, Dam I, Jorgensen C, Krogsdam AM, Holst D, Kratchmarova I, Gottlicher M, Gustafsson JA, Berge R, Flatmark T, Knudesen J et al: Acyl-CoA esters antagonize the effects of ligands on peroxisome proliferator-activated receptor a conformation, DNA binding, and interaction with co-factors. J Biol Chem (2001) 276(24):21410-21416.
51. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J: Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem (1997) 272(45):28210-28217.
52. Dallongeville J, Bauge E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, Staels B: Peroxisome proliferator-activated receptor α is not rate-limiting for the lipoprotein-lowering action of fish oil. J Biol Chem (2001) 276(7):4634-4639.
53. Pan DA, Mater MK, Thelen AP, Peters JM, Gonzalez FJ, Jump DB: Evidence against the peroxisome proliferator-activated receptor α (PPARα) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription. J Lipid Res (2000) 41(5):742-751.
54. Marrapodi M, Chiang JY: Peroxisome proliferator-activated receptor α (PPARα) and agonist inhibit cholesterol 7α-hydroxylase gene (CYP7A1) transcription. J Lipid Res (2000) 41(4):514-520.
55. Shih DQ, Dansky HM, Fleisher M, Assmann G, Fajans SS, Stoffel M: Genotype/phenotype relationships in HNF-4α/MODY1: Haplo insufficiency is associated with reduced apolipoproteins (AII), apolipoprotein (CIII), lipoprotein (a), and triglyceride levels. Diabetes (2000) 49(5):832-837.
56. Stoffel M, Duncan SA: The maturity-onset diabetes of the young (MODY1) transcription factor HNF-4α regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci USA (1997) 94(24):13209-13214.
57. Grundy SM, Denke MA: Dietary influences on serum lipids and lipoproteins. J Lipid Res (1990) 31(7):1149-1172.